H

Hoth Therapeutics

D
HOTH
USD
-0.0098
(-0.9802%)
Market Closed
12,128.00
Volume
-1.285
EPS
-
Div Yield
-0.638710
P/E
6,834,765.96
Market Cap
Today
-0.9802%
1 Week
-13.158%
1 Month
33.315%
6 Months
-26.119%
12 Months
-40.361%
Year To Date
-31.250%
All Time
-99.357%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Thailand's Economy Stumbles as Regional Peers Improve

04.04.2024
Economy news
More
Related Instruments
R
REKR
0.025
(2.0833%)
USD
S
SRNE
(%)
USD
O
OCUL
-0.005
(-0.0552%)
USD
M
MRNS
0.075
(4.918%)
USD
B
BNGO
0.0207
(5.0748%)
USD

Title:
Hoth Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Do you need help or have a question?
Contact Us